Isomorphic Labs, Founded by Nobel Laureate Demis Hassabis, Secures Record $2.1B Series B to Advance AI-Driven Drug Discovery

May 13, 2026 11:55 CST Updated 11:55

Isomorphic Labs

AI Drug Developer

Official Announcement!

Today,Incubated by GoogleTheAIPharmaceuticalsIsomorphic LabsAnnounced that it has raised$2.1 billion in Series B financing.

This latest round of investment will accelerate the company's pioneering new artificial intelligence modelThe evolution towards large-scale applications.

This funding round was led by Thrive Capital, with participation from existing backers Alphabet and GV, and new investors including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

Including the $600 million Series A financing in March 2025,The company's total financing will approach $3 billion within a year and a half.

The new funding will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of clinical therapeutic programs.

In addition, the funds will support the company by integrating world-class artificial intelligence, engineering, drug design, and clinical talent.

The Biggest Bet in AI Drug Discovery History

Isomorphic LabsFounded in2021By the end of the year, it was transformed from Google's DeepMind team.

Founder andCEOFor2024Nobel Prize in Chemistry WinnerDemis Hassabis, whose mission is to applyAITreat all diseases.

The team developed AlphaFold2, which became a milestone in the history of AI + life sciences and won the 2024 Nobel Prize.

Backed by a Nobel Prize-winning team and supported by Google, Isomorphic Labs embarked on its journey with ambitious plans:

“UseAIRedefining Drug Discovery”。

The development of traditional drugs takes an average of ten years and costs billions of dollars.And the success rates and methods for developing drugs targeting different targets vary.

As for Isomorphic LabsIn useAICreate a universal drug design engine that can not only be used for a single target or a single drug type, but also be repeatedly applied to any different disease areas.

2024Year5Month,Following the AlphaFold route,IsomorphicUnitedDeepMindJointly releasedAlphaFold3, which can predict the structure and interactions of all biomolecules, becoming a revolutionary tool for drug development.

April 2025Month, CompanyAnnounced the acquisition of6Billion US dollarsTheHuge AmountFinancing, byThrive CapitalLead investment,GVAndAlphabetFollow-on investment. This funding will be used to support theirAIDrug design engine, and help them advance internal projects into the clinical stage。

In February this year, Isomorphic LabsphicLaunchIsoDDE, is currently the strongest globallyDrug DesignModel A.

It predicts small molecule binding affinity with accuracy surpassing physics-based methods, and in protein-ligand structure prediction, its accuracy is more than double that of AlphaFold3.

The release of this model immediately sparked significant attention in the biopharmaceutical industry.

Now,IsomorphicWith multinational pharmaceutical companiesNovartisAndEli LillySigned a Major Research Collaboration，Total amount exceeds30Billion US dollars.

Not long ago (4Month16Day), President of the CompanyMax Jaderberg said:"Our drug is about to enter the clinical stage, and we will begin to see the efficacy of these molecules, which will be a very exciting moment."

The specific time, specific therapy, and specific targets have not been confirmed, but it has exceeded the previously estimated 2025 start of clinical trials.Bottom.

Regarding this round of financing, the founder& CEODemis Hassabis"This round of financing represents a significant vote of confidence from a diverse group of top international investors in our AI-first approach to drug design and development."

"Now that we have proven the fundamental approach, our focus is on scaling the technology to its full potential. This capital injection enables us to build out our drug design engine at scale and advance our mission to solve all diseases."

—The End—

Recommended Reading